Skip to main content

Towers Christopher's Form 4 filing

Intelligent Bio Solutions Inc. (INBS) · filed Oct 6, 2023

Accession no.
0001493152-23-036582
Filed
Oct 6, 2023
Trade date
Oct 4, 2023
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction and 2 derivative transactions. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Towers ChristopherCIK 0001775875Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 4, 2023Common StockPPurchaseAcquired+9,090–F1–9,880Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Oct 4, 2023Common StockPPurchaseAcquired+9,090–F1–9,090Direct
Oct 4, 2023Common StockPPurchaseAcquired+9,090–F1–9,090Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The reported securities are included within 9,090 INBS Class A Units purchased by the reporting person for $0.55 per Unit. Each Unit consists of one share of the common stock, one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series E Warrants"), and one warrant to purchase one share of Common Stock at an exercise price of $0.55 per share ("Series F Warrants"). The Warrants will be exercisable beginning on the effective date of such stockholder approvals as may be required by the applicable rules and regulations of the Nasdaq Capital Market (or any successor entity) to permit the exercise of the Warrants ("Warrant Stockholder Approval").

Referenced by the price of 1 transaction in Table I and 2 transactions in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)